Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H12O6 |
Molecular Weight | 336.295 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(CC2=C(O)C3=CC=CC=C3OC2=O)C(=O)OC4=CC=CC=C14
InChI
InChIKey=DOBMPNYZJYQDGZ-UHFFFAOYSA-N
InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2
DescriptionSources: https://www.drugbank.ca/drugs/DB00266Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728
Sources: https://www.drugbank.ca/drugs/DB00266
Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728
Dicumarol is an coumarin-like compound found in sweet clover. It is used as oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Dicumarol is also used in biochemical experiments as an inhibitor of reductases.
Originator
Sources: http://www.jbc.org/content/138/1/21.full.pdf
Curator's Comment: Campbell, H.A. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry, 138, 21–33.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1930 Sources: https://www.drugbank.ca/drugs/DB00266 |
2.0 µM [IC50] | ||
Target ID: CHEMBL3623 Sources: https://www.drugbank.ca/drugs/DB00266 |
10.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugbank.ca/drugs/DB00266 |
Preventing | DICUMAROL Approved UseFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis. Launch Date1944 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
521 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.84 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.03% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/54415/ |
6 mg/kg single, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DICUMAROL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day steady, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 59.8+15.3 years n = 71 Health Status: unhealthy Age Group: 59.8+15.3 years Sex: M+F Population Size: 71 Sources: |
|
2100 mg single, oral Overdose |
unknown n = 1 |
Disc. AE: Distended blood vessels... AEs leading to discontinuation/dose reduction: Distended blood vessels (1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Distended blood vessels | 1 patient Disc. AE |
2100 mg single, oral Overdose |
unknown n = 1 |
PubMed
Title | Date | PubMed |
---|---|---|
Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma. | 1990 |
|
Dicoumarol and warfarin. | 1991 Aug |
|
[Fatal cerebral hemorrhage caused by overdose of dicumarol, report of a case]. | 1992 Feb |
|
Identification and characterization of the enzymatic activity of zeta-crystallin from guinea pig lens. A novel NADPH:quinone oxidoreductase. | 1992 Jan 5 |
|
Reduction of chromium(VI) to chromium(V) by rat liver cytosolic and microsomal fractions: is DT-diaphorase involved? | 1992 Jul |
|
Inhibition kinetics of camel lens zeta-crystallin: multiple inhibition studies. | 1996 Aug |
|
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease. | 1996 Jun 21 |
|
Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. | 1996 May 10 |
|
Coumarin-based inhibitors of HIV integrase. | 1997 Jan 17 |
|
Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. | 2001 Apr |
|
Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol. | 2001 Jun 1 |
|
P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. | 2003 Dec 9 |
|
Improving relative bioavailability of dicumarol by reducing particle size and adding the adhesive poly(fumaric-co-sebacic) anhydride. | 2003 Jul |
|
Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. | 2003 Sep 1 |
|
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. | 2004 May 1 |
|
Mitochondrial production of reactive oxygen species mediate dicumarol-induced cytotoxicity in cancer cells. | 2006 Dec 8 |
|
Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells. | 2007 Nov 1 |
|
The catecholaminergic RCSN-3 cell line: a model to study dopamine metabolism. | 2008 May-Jun |
|
NAD(P)H quinone oxidoreductase 1 is essential for ozone-induced oxidative stress in mice and humans. | 2009 Jul |
|
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells. | 2009 Jul 15 |
|
Low levels of the air pollutant 1-nitropyrene induce DNA damage, increased levels of reactive oxygen species and endoplasmic reticulum stress in human endothelial cells. | 2009 Jul 28 |
|
Analysis of couch position tolerance limits to detect mistakes in patient setup. | 2009 Oct 29 |
|
Cost-effective interrogation of single nucleotide polymorphisms using the mismatch amplification mutation assay and capillary electrophoresis. | 2010 Dec |
|
Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. | 2011 Aug |
|
Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. | 2011 Jun |
|
Cross talk between keratinocytes and dendritic cells: impact on the prediction of sensitization. | 2011 Oct |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2113031
Dicoumarol inhibits rat liver microsomal vitamin K epoxide reductase with IC50=2 uM and cytosolic DT-diaphorase with IC50=0.05 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C45597
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
||
|
WHO-VATC |
QB01AA01
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
||
|
WHO-ATC |
B01AA01
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07101MIG
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
DB00266
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
17860
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
3223
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
DICOUMAROL
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
4513
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
DICUMAROL
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | Description: A white or creamy white, crystalline powder; odour, characteristic, faint.Solubility: Practically insoluble in water, ethanol (~750 g/l) TS and ether R.Category: Anticoagulant.Storage: Dicoumarol should be kept in a well-closed container, protected from light.Definition: Dicoumarol contains not less than 98.5% and not more than 101.0% of C19H12O6, calculated with reference to the dried substance. | ||
|
7QID3E7BG7
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
D001728
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
221570
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
54676038
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
100000082921
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
6808
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
dicoumarol
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
2897
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
200-632-9
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
1598
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1466
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
41834
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
C310
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
66-76-2
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
867
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | |||
|
m4370
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID8021729
Created by
admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY